Calamos Advisors
FLGT icon

Calamos Advisors’s Fulgent Genetics FLGT Stock Holding History

Calamos Advisors’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-50,852
Closed -$656K – 733
2019
Q4 		$656K Buy
+50,852
New +$604K ﹤0.01% 692

Other funds holding FLGT

CFW
CA Family Wealth Beverly Hills, California $94.9M AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return
RJT
Raymond James Trust St. Petersburg, Florida $4.6B AUM 33.54% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
HIM
Hillsdale Investment Management Toronto, Ontario, Canada $3.68B AUM 62.12% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Calamos Advisors's FLGT Position: Q1 2020 in Review

Calamos Advisors sold out of Fulgent Genetics (FLGT) in Q1 2020, closing a stake of 50,852 shares — an estimated $656K sold.

Calamos Advisors first reported a position in FLGT in Q4 2019 and held it in 1 quarter. The position peaked at $656K in Q4 2019. 75 funds tracked by Wall St. Rank hold FLGT as of Q1 2020.

  • Calamos Advisors reported no remaining Fulgent Genetics position as of Q1 2020 after selling out during the quarter.
  • Calamos Advisors sold 50,852 Fulgent Genetics shares in Q1 2020, an estimated $656K.
  • Calamos Advisors first reported a position in Fulgent Genetics in Q4 2019 and held it in 1 quarter.
  • Calamos Advisors's Fulgent Genetics position peaked at $656K in Q4 2019.
  • 75 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2020.

Based on Calamos Advisors's 13F filing for Q1 2020, filed 28 Apr 2020.